²é¿´: 1218  |  »Ø¸´: 3
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

[½»Á÷] ÇóÖú·­ÒëÖÐÎÄÕªÒªÒ»·Ý£¬ÖØÉͽð±Ò£¬·­ÒëµÄºÃ¿É×·¼Ó

Ô­ÎÄ£º

¹ú²úÀûÅàͪÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§·ÖÎö

ÕªÒª£ºÄ¿µÄ£ºÌ½ÌÖ¹ú²úÀûÅàͪ£¨Ë¼ÀûÊæ£©ÖÎÁÆÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­ÁÆÐ§ºÍ°²È«ÐÔ¡£·½·¨£ºËæ»ú³éÈ¡ÄÔѪ¹Ü²¡ËùÖ¾«ÉñÕϰ­30Àý£¬ÓÃ˼ÀûÊæÖÎÁÆ£¬²¢·Ö±ðÓÚÖÎÁÆÇ°¼°ÖÎÁƺóµÚ1¡¢2¡¢4¡¢8ÖÜÄ©²ÅÈ¥¼òÃ÷¾«Éñ²¡Á¿±í£¨BPRS)¡¢ÑôÐÔÖ¢×´ÒõÐÔÖ¢×´Á¿±í£¨PANSS£©¼°¸±×÷ÓÃÁ¿±í£¨TCSS£©ÆÀ¶¨ÁÙ´²ÁÆÐ§¼°²»Á¼·´Ó¦¡£½á¹û£ºBPRS×Ü·Ö¡¢PANSS×ֺܷ͸÷Ö¢×´ÆÀ·Ö¾ù½ÏÖÎÁÆÇ°ÏÔÖø½µµÍ£¬ÇÒÓÐÏÔÖø²îÒ죨P<0.01~0.05£©£¬ÓÐЧÂÊ£º90%£¬ÏÔЧÂÊ£º63%£¬³£¼û²»Á¼·´Ó¦ÊÇÌåÖØÔö¼Ó¡¢¾²×ø²»ÄÜ¡£½áÂÛ£ºË¼ÀûÊæ¶ÔÄÔѪ¹ÜËùÖª¾«ÉñÕϰ­°²È«ÓÐЧ£¬²»Á¼·´Ó¦ÉÙ£¬¾­¼ÃÊÊÓã¬ÖµµÃÁÙ´²ÍƹãʹÓá£
ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

·Ç±ÈѰ³£

ľ³æ (СÓÐÃûÆø)

xiaotongxyz(½ð±Ò+20, ·­ÒëEPI+1):·­ÒëµÄ²»¹»×¨Òµ£¬ÓÐЩ·­Òë²»¹»×¼È·×¨Òµ 2010-04-30 01:18
Analysis of therapeutic effect of domestic Risperidone on non-psychotic disorders
resulting from cerebrovascular diseases

Abstract:
Purpose: to probe into therapeutic effect and security of domestic Risperidone on non-psychotic disorders resulting from cerebrovascular diseases.
Approach: to randomly draw 30 cases with non-psychotic disorders resulting from cerebrovascular diseases, treat them with Risperidone and then assess clinical curative effects and undesirable reactions with BPRS, PANSS and TCSS at the end of the first, second, fourth and eighth week before and after treatment. Result: aggregate score of BPRS and PANSS and each symptom score are considerablely much lower than that before treatment with significant variation
(P<0.01~0.05). The effective rate is 90% and developing rate is 63%. Common undesirable reactions are gain in weight and loss of sitting still.
Conclusion: Risperidone is secure and effective with a few undesirable reactions and deserves promotion and application because of its economically affordable and applicable trait on the treatment of non-psychotic disorders resulting from cerebrovascular diseases.
ѧ»áÈ¡Éᣡ
2Â¥2010-04-29 21:53:09
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

pharmjackie

ľ³æ (ÕýʽдÊÖ)

xiaotongxyz(½ð±Ò+30):ǰ°ë²¿·Ö·­ÒëºÜºÃ£¬ºó°ë²¿·Ö²»¹»ÀíÏ룬רҵÐÔÔÙǿЩ¾ÍºÃÁË 2010-04-30 01:22
efficacy of Risperidone on brain vascular diseases caused psychonosema

Abstract  Object: to evaluate the efficacy and safety of Risperidone on brain vascular diseases caused psychonosema. Method: A total of 30 patients with psychonosema was randomly selected to treat with Risperidone, and clinical efficacy and adverse effect was recorded using BPRS, PANSS, and TCSS before treatment and at the end of 1, 2, 4, 8 weeks after treatment. Results: BPRS scores, PANSS scores and symptom scores decreased significantly compared to that of pre-treatment (P<0.01~0.05). Effective percentage is 90% while the obvious effective rate is 63%. Common adverse effects include: Weight gain, akathisia. Conclusion: Risperidone¡¯s effectiveness, safety and minor adverse effect makes itself worthy of clinical use.
3Â¥2010-04-29 22:10:21
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xiaotongxyz

ľ³æ (ÕýʽдÊÖ)

ÇóÖú½áÊø£¬ÉêÇë³·ÏúÌû×Ó£¬Í˻ؽð±Ò

ÇóÖúÒѽâ¾ö£¬ËäÓд𸴣¬µ«ÊDz»ÂúÒâ½á¹û£¬ÉêÇëÍË»ØÊ£Óà½ð±Ò
ÎÒ²»ÊÇÒ»¸öËæ±ãµÄÈË£¬ÎÒËæ±ãÆðÀ´²»ÊÇÈË£¬¹þ¹þ
4Â¥2010-05-07 11:58:31
ÒÑÔÄ   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ xiaotongxyz µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 265Çóµ÷¼Á +4 ÁºÁºÐ£Ð£ 2026-03-19 4/200 2026-03-20 00:03 by 23Postgrad
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á +9 Ymlll 2026-03-18 12/600 2026-03-20 00:01 by 23Postgrad
[ÂÛÎÄͶ¸å] ÉêÇë»Ø¸åÑÓÆÚÒ»¸öÔ£¬±à¼­Í¬ÒâÁË¡£µ«ÏµÍ³ÉϵÄʱ¼äû±ä£¬¸ø±à¼­ÓÖдÓʼþÁË£¬Ã»»Ø¸´ 10+3 wangf9518 2026-03-17 4/200 2026-03-19 23:55 by babero
[¿¼ÑÐ] 081700»¯¹¤Ñ§Ë¶µ÷¼Á +3 ¡¾1¡¿ 2026-03-16 3/150 2026-03-19 23:40 by edmund7
[¿¼ÑÐ] 0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑо­Àú ÓжþÇøÎÄÕ +18 rare12345 2026-03-18 18/900 2026-03-19 22:36 by ѧԱ8dgXkO
[¿¼ÑÐ] Çóµ÷¼Á +3 Mqqqqqq 2026-03-19 3/150 2026-03-19 14:11 by peike
[¿¼ÑÐ] 332Çóµ÷¼Á +3 ydfyh 2026-03-17 3/150 2026-03-19 10:14 by ¹¦·ò·è¿ñ
[½Ìʦ֮¼Ò] ½¹ÂÇ +9 Ë®±ùÔÂÔÂÒ°Íà 2026-03-13 13/650 2026-03-19 09:50 by otani
[¿¼ÑÐ] 344Çóµ÷¼Á +6 knight344 2026-03-16 7/350 2026-03-18 20:13 by walc
[¿¼ÑÐ] 303Çóµ÷¼Á +4 î£08 2026-03-17 6/300 2026-03-18 11:01 by Iveryant
[¿¼ÑÐ] 265Çóµ÷¼Á +3 ÁºÁºÐ£Ð£ 2026-03-17 3/150 2026-03-18 09:12 by zhukairuo
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] ²ÄÁÏר˶326Çóµ÷¼Á +6 Ä«ìÏæ¦Ý· 2026-03-15 7/350 2026-03-17 17:10 by ruiyingmiao
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤×¨Ë¶µ÷¼Á +5 heming3743 2026-03-16 5/250 2026-03-17 14:03 by Ó¸ÒÌ«¼àÍõ¹«¹«
[¿¼ÑÐ] 278Çóµ÷¼Á +3 Yy7400 2026-03-13 3/150 2026-03-17 08:24 by laoshidan
[¿¼ÑÐ] [µ¼Ê¦ÍƼö]Î÷ÄϿƼ¼´óѧ¹ú·À/²ÄÁϵ¼Ê¦ÍƼö +3 ¼â½ÇСºÉ 2026-03-16 6/300 2026-03-16 23:21 by ¼â½ÇСºÉ
[¿¼ÑÐ] ҩѧ383 Çóµ÷¼Á +3 ҩѧchy 2026-03-15 4/200 2026-03-16 20:51 by Ôª×Ó^0^
[¿¼ÑÐ] 277²ÄÁÏ¿ÆÑ§Ó빤³Ì080500Çóµ÷¼Á +3 ×ÔÓɼå±ý¹û×Ó 2026-03-16 3/150 2026-03-16 14:10 by ÔËÆøyunqi
[¿¼ÑÐ] Öпƴó²ÄÁÏר˶319Çóµ÷¼Á +3 ÃÏöβÄÁÏ 2026-03-13 3/150 2026-03-14 18:10 by houyaoxu
[¿¼ÑÐ] 304Çóµ÷¼Á +7 7712b 2026-03-13 7/350 2026-03-13 21:42 by peike
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û